Clinical Trial Update: Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports withdrawal of a Phase 1/2 study evaluating a reduced conditioning regimen with 90Y-epratuzumab radioimmunotherapy before allo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia
• Cd22-positive B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• 90Y-epratuzumab (epratuzumab)

Snippet

Sponsor: Nantes University Hospital | Conditions: Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN